Blog

Sodium valproate (VPA) and lamotrigine (LTG) are the broad-spectrum anticonvulsants drugs used in both generalized and partial seizures. Weight gain is a well-known adverse effect of VPA treatment occurring in up to 71% of exposed patients, although typically the rate is around 10%1. Weight gain is the most common reason for patients to discontinue VPA treatment2–4. In a study, 38% of VPA-treated patients gained more than 10% of their body weight compared with 8% of patients treated with LTG5. Further, weight gain associated with VPA seems to be appetite-related and not metabolic6.